GCGR抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: LOVO cell, Mouse heart tissue lysates, Primary antibody: P04904(GCGR Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P04904(GCGR Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The glucagon receptor (GCGR), a class B G protein-coupled receptor (GPCR), plays a critical role in glucose homeostasis by mediating the effects of glucagon, a hormone that elevates blood sugar levels. GCGR antibodies are tools developed to study or modulate this receptor's activity. Structurally, GCGR consists of an extracellular domain for glucagon binding and a transmembrane domain for signal transduction. Dysregulation of GCGR signaling is linked to metabolic disorders, including type 2 diabetes and hyperglucagonemia, making it a therapeutic target.

GCGR antibodies are primarily used in research to visualize receptor localization, quantify expression levels in tissues, or block/interfere with glucagon binding. Monoclonal antibodies targeting specific GCGR epitopes have been explored for therapeutic purposes, such as inhibiting excessive hepatic glucose production in diabetes. Conversely, agonistic antibodies could theoretically mimic glucagon's effects, though this approach is less common due to the risk of hyperglycemia. Additionally, autoantibodies against GCGR are occasionally studied in autoimmune contexts, though their clinical relevance remains unclear.

Recent advancements in antibody engineering, including humanized or recombinant formats, aim to enhance specificity and reduce immunogenicity. Challenges include ensuring tissue selectivity to avoid off-target effects and optimizing pharmacokinetics. Overall, GCGR antibodies serve as both investigative tools and potential therapeutics, bridging insights into receptor biology and metabolic disease management.